D. Boral Capital Reaffirms “Buy” Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $25.00 price objective on the stock. D. Boral Capital’s target price would suggest a potential upside of 444.66% from the company’s current price.

A number of other research analysts have also recently weighed in on HUMA. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th. Benchmark boosted their price objective on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, December 23rd. BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. TD Cowen restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Finally, Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $13.71.

Humacyte Stock Performance

Humacyte stock opened at $4.59 on Tuesday. The company has a market capitalization of $577.70 million, a price-to-earnings ratio of -3.43 and a beta of 1.32. Humacyte has a fifty-two week low of $2.80 and a fifty-two week high of $9.97. The stock has a fifty day moving average of $4.54 and a two-hundred day moving average of $5.65.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). During the same quarter last year, the firm earned ($0.25) earnings per share. On average, analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brookstone Capital Management bought a new stake in Humacyte in the fourth quarter valued at about $56,000. ACT Wealth Management LLC bought a new position in shares of Humacyte during the fourth quarter valued at approximately $57,000. Concurrent Investment Advisors LLC bought a new position in shares of Humacyte during the third quarter valued at approximately $75,000. FORA Capital LLC bought a new position in shares of Humacyte during the third quarter valued at approximately $96,000. Finally, Insigneo Advisory Services LLC bought a new position in shares of Humacyte during the third quarter valued at approximately $109,000. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.